The working hypothesis was that in COVID-19, tissue ACE2 is lowered, leading to unopposed ACE activity and high Ang II levels as well as impaired organ protection, and that signs of this activity are reflected in the serum protease activity and measurable using the neuropeptide reporter assay (NRA). This evidence concerns the gene ACE and COVID-19.